VE-cadherin Antibody (BV9): sc-52751

VE-cadherin Antibody (BV9) is a mouse monoclonal IgG2a kappa light chain antibody that targets VE-cadherin, also known as CDH5 or Cadherin-5, a critical calcium-dependent adhesion molecule located at the intercellular junctions of endothelial cells. Anti-VE-cadherin antibody (BV9) is raised against a recombinant extracellular domain of human VE-cadherin, enabling the detection of VE-cadherin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). VE-cadherin plays a role in maintaining vascular integrity by mediating cell-cell adhesion, which is essential for the cohesion and organization of endothelial layers. VE-cadherin′s presence at intercellular junctions ensures the stability of blood vessels and regulates vascular permeability, making it vital for processes like angiogenesis and vascular remodeling. The extracellular domain of VE-cadherin contains multiple homologous repeats that facilitate specific binding between endothelial cells, while the intracellular domain interacts with proteins like β-catenin to influence intracellular signaling pathways and cadherin function. VE-cadherin monoclonal antibody (BV9) is available in both non-conjugated form and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing researchers with flexibility for diverse experimental setups. Anti-VE-cadherin antibody (BV9) is recommended for researchers studying vascular biology, cancer metastasis, and inflammatory responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VE-cadherin Antibody (BV9) has 65 citations in a variety of scientific publications.

Primary antibodies like Anti-VE-cadherin Antibody (BV9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VE-cadherin Antibody (BV9) Specifications

Alternate Product Name: Cadherin 5

Product Clone Name: BV9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids:

Epitope Target: VE-cadherin

Epitope Species: human

Product Reactivity/Detection: VE-cadherin

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 65 citations in various scientific publications

Available Conjugates/Forms for VE-cadherin Antibody (BV9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred VE-cadherin antibody is VE-cadherin Antibody (F-8): sc-9989.